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Abstract. Nilsson AG, Sundh D, B€ackhed F, Lorentzon
M (University of Gothenburg, Gothenburg, Sweden;
Sahlgrenska University Hospital, Gothenburg and
M€olndal, Sweden; and University of Copenhagen,
Copenhagen, Denmark). Lactobacillus reuteri
reduces bone loss in older women with low bone
mineral density: a randomized, placebo-controlled,
double-blind, clinical trial. J Intern Med 2018; 284:
307–317.
Background. The importance of the gut microbiome for
bone metabolism in mice has recently been demon-
strated, but no studies are available in humans.
Lactobacillus reuteri ATCCPTA 6475 (L. reuteri
6475) has been reported to increase bone mineral
density (BMD) in mice but its effect on the human
skeleton is unknown. The objective of this trial was
to investigate if L. reuteri 6475 affects bone loss in
older women with low BMD.
Methods. In this double-blind, placebo-controlled
study, women from the population who were 75
to 80 years old and had low BMD were randomized
to orally receive 1010 colony-forming units of
L. reuteri 6475 daily or placebo. The predefined
primary end-point was relative change after
12 months in tibia total volumetric BMD (vBMD).
Results. Ninety women were included and 70 com-
pleted the study. L. reuteri 6475 reduced loss of
total vBMD compared to placebo both in the
intention-to-treat (ITT) analysis [0.83% (95% con-
fidence interval [CI], 1.47 to 0.19%) vs. 1.85%
(95% CI, 2.64 to 1.07%); mean difference 1.02%
(95% CI, 0.02–2.03)] and per protocol analysis
[0.93% (95% CI, 1.45 to 0.40) vs. 1.86%
(95% CI, 2.35 to 1.36); mean difference 0.93%
(95% CI, 0.21–1.65)]. In general, similar but
smaller effects were observed in the secondary
bone variable outcomes, but these differences did
not reach statistical significance in the ITT popu-
lation. Adverse events did not differ between
groups.
Conclusions. Supplementation with L. reuteri 6475
should be further explored as a novel approach to
prevent age-associated bone loss and osteoporosis.
Keywords: lactobacillus reuteri, osteoporosis, probi-
otics, volumetric bone mineral density.
Introduction
Osteoporosis is a disease characterized by loss of
bone density and deteriorated bone microstruc-
ture, resulting in reduced bone strength and
increased risk of fracture [1, 2]. Osteoporotic
fractures are usually caused by low energy trauma
and are very common, affecting every second
woman and every fourth man after 50 years of
age [3]. In 2005, there were over 2 million fractures,
costing almost USD 17 billion, in the United States
alone [4]. Pharmacological treatment that effec-
tively reduces the risk of fracture [5] is available
but treatment rates and adherence to medication
in patients with high fracture risk remain low,
possibly due to fear of rare side effects [6].
The human gastrointestinal tract is the host for
several trillions of microbial cells, suggested to
have many important physiological functions in
the host, including regulation of the immune
system, intestinal endocrine signaling, protection
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against pathogen overgrowth, biosynthesis of vita-
mins and serving as a source of energy biogenesis
[7, 8]. Dysbiosis of the gut microbiota has been
implicated in diseases such as obesity, diabetes
mellitus and autoimmune diseases [8]. It has
become increasingly clear that that the gut micro-
biome also modulates bone homoeostasis in mice,
potentially by regulating the immune system and
osteoclast formation [9, 10], suggesting that mod-
ulating the microbiome and/or inflammatory tone
may provide means to modulate bone mass and
prevent osteoporosis.
Lactobacillus reuteri ATCC PTA 6475 (L. reuteri
6475) is a microbe indigenous to the human
gastrointestinal tract [11] and has potential host
benefits including anti-inflammatory properties
[12, 13]. Inflammation leads to accelerated bone
loss due to stimulation of osteoclastogenesis and
increased bone resorption [14]. L. reuteri 6475
supplementation was recently reported to prevent
ovariectomy-induced bone loss in mice [15] and
increases trabecular bone density in female mice
with active inflammation [16]. The effect of probi-
otic supplementation on the human skeleton is
unknown.
In this randomized, double-blind, placebo-con-
trolled trial, it was investigated if daily supplemen-
tation with L. reuteri 6475 could reduce bone loss
in older women with low BMD.
Methods
Study design
The study ‘Effects of Lactobacillus reuteri on Bone
in Older Women’ (ELBOW) was a double-blind,
randomized, placebo-controlled, single-centre
trial, performed at the Geriatric Medicine Unit at
Sahlgrenska University Hospital in M€olndal, Swe-
den. The study was approved by the Regional
Ethics Committee in Gothenburg, D-nr 075-15
(26 February 2015) and addendum T229-16 (10
March 2016). The study was registered at Clinical-
trials.gov (number NCT02422082) prior to study
start.
Participants
Study subjects were recruited from women who
participated in a larger population-based study
(Sahlgrenska University hospital Prospective Eval-
uation of the Risk of Bone fractures, SUPERB) [17].
Inclusion criteria were willingness to participate,
availability throughout the study period, and a T-
score ≤1 standard deviation (SD) for bone mineral
density (BMD) at the spine, hip or femoral neck
measured by dual energy X-ray absorptiometry
(DXA). Exclusion criteria were as follows: osteo-
porosis defined as T-score <2.5 at the spine or the
total hip; untreated hyperthyroidism; rheumatoid
arthritis; a diagnosis during the last year of chronic
obstructive pulmonary disease, inflammatory
bowel disease, celiac disease, or diabetes; malig-
nancy diagnosed during the last 5 years; or med-
ication with oral glucocorticoids, antiresorptive
therapy, teriparatide during the last 3 years, or
antibiotics during the last 2 months. All study
subjects gave their written informed consent prior
to inclusion.
Randomisation and masking
The sponsor (BioGaia AB) provided 120 sequen-
tially numbered containers, based on a random-
ization of 120 study subjects into 20 blocks (6 in
each block) and was generated using the Web site
Randomization.com ⟨http://www.randomization.
com⟩. Study subjects were consecutively assigned
to study numbers. The study product and placebo
were given in identical stick-packs and were pro-
vided by research nurses to study subjects, both
without knowledge of supplement type (double
blinded). Blinding was maintained for all until
study end, completion of the statistical analysis
plan and database lock.
Procedures
The study product was freeze-dried L. reuteri 6475
(BioGaia AB, Stockholm, Sweden) in doses of 5x109
colony-forming units (CFU) mixed with maltodex-
trin powder, filled in stick packs, and was taken
twice daily, yielding a total daily dose of
1x1010 CFU day1. The placebo product consisted
of maltodextrin powder. Study participants were
instructed to ingest the powder after it was mixed
with a cold and nonalcoholic containing food or
drink.
A standardized questionnaire was used to collect
information about smoking habits, calcium sup-
plementation, alcohol intake, medical history,
medications and physical activity [17]. Volumetric
BMD (vBMD) and bone microstructure were inves-
tigated, at baseline and after 12 months, in the
distal tibia with high-resolution peripheral quanti-
tative computed tomography (HR-pQCT; XtremeCT,
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Scanco medical AG, Br€uttisellen, Switzerland) with
a protocol described earlier [18]. After processing
the images, as previously described [19], the follow-
ing variables were obtained: total volumetric BMD
(vBMD, mg cm3), cortical thickness (Ct.Th, mm),
cortical volumetric BMD (vBMD, mg cm3), trabec-
ular bone volume fraction (%). The coefficients of
variation (CVs) at our unit, assessed in 30 women
aged 75–80 years, were 0.2% (total vBMD), 0.5%
(Ct.Th), 0.3% (cortical vBMD) and 0.5% (trabecular
bone volume fraction). Areal BMD (aBMD, g cm2)
was measured at the total hip, femoral neck and
lumbar spine (L1-L4), and body composition of the
total body, using a Hologic Discovery A DXA
(Hologic, Waltham, MA, USA). The CVs for aBMD
measurements at our unit for women aged 75–
80 years were 0.8% for total hip, 1.3% for femoral
neck and 0.7% for lumbar spine.
Serum samples were immediately frozen after col-
lection. Analysis of HbA1c was conducted on HPLC
(ion exchange liquid chromatography) with the
Mono-S 5/50 GL Tricorn column (GE Healthcare,
Uppsala, Sweden). The coefficient of variation for
reproducibility was 1.17%, and the correlation
coefficient for linearity with IFCC reference was
0.9992. All other serum analyses were performed
in duplicate using immunoassays by TECO med-
ical AG (Sissach, Switzerland): N-telopeptide of
type I collagen (NTx; Osteomark; Alere Scarbor-
ough, Inc., Scarborough, ME, USA; intra- and
inter-assay variability 4.6 and 6.9%, respectively),
bone-specific alkaline phosphatase (BAP; Micro-
vueTM; Quidel Corporation, Athens, OH, USA;
intra- and inter-assay variability 5.0 and 5.9%,
respectively), high sensitivity c-reactive protein
(hsCRP; BioMerica, Inc., Irvine, CA, USA; intra-
and inter-assay variability 4.4 and 3.3%, respec-
tively) and tumour necrosis factor-a (TNF-a;
Quantikine; R&D Systems, Inc., Minneapolis,
MN, USA; intra- and inter-assay variability 2.0
and 6.7%, respectively).
Outcomes
Primary outcome was relative change after
12 months in tibia total vBMD, and secondary
outcomes were relative changes after 12 months in:
aBMD measured at the hip and spine; trabecular
bone volume fraction; cortical vBMD; cortical thick-
ness; serum markers for bone turnover (N-terminal
telopeptide and bone-specific alkaline phos-
phatase); serum markers for inflammation (C-reac-
tive protein and tumour necrosis factor alpha);
serum HbA1c; and body composition (total fat and
lean mass). Study subjects visited the clinic every
third month to collect more study product and for
assessment of adherence and adverse events.
Statistical analyses
A statistical analysis plan was developed before
unblinding. Missing data were handled by multiple
imputation methodology with 50 study samples
including patient characteristics, medical history
and prior medications that were associated with at
least r ≥ 0.40 to any of the outcome variables or
absolute values of those at 12 months or with
missingness of any of the outcome variables at
≤0.10 significance level. Baseline measurements for
the outcome variables were also included in the
imputation regressionmodel, but no follow-up data.
Hence, the following variables were used for imputa-
tion: age, height, secondary osteoporosis, fracture
after age of 50 and all baseline variables for the
studied efficacy outcomes. A few variables, for exam-
ple diabetes, inflammatory bowel disease, meno-
pause before 45 years, that lead to model
convergence problems, were excluded. The impu-
tations were performed separately per treatment
group to avoid cross-contamination of imputation
models and separately for each outcome using
PROC MI procedure in SAS Software with fully
conditional specification with regression method.
The results were pooled using PROC MIANALYZE
procedure. A seed was decided ahead of performed
analyses.
The difference between the treatment groups with
respect to efficacy variableswas testedby analysis of
covariance (ANCOVA) with relative change from base-
line to 12 months as dependent variable, treatment
group as fixed effect and baseline value as covariate.
Fromthismodel, least squaremeans (LSM)with95%
confidence intervals (CI) with P-values were pre-
sented. The P-value for the relative change from
baseline within the two groups was obtained from
the same model, and normality checks were per-
formed. For tests between the two treatment groups,
Fisher’s exact test was used for dichotomous vari-
ables, two-sample t-test orMann–Whitney U-test for
normally and not normally distributed continuous
variables, respectively.
The primary and all secondary variables were
analysed both for the intention-to-treat (ITT; all
randomized subjects) and per protocol (PP) popu-
lation (those who completed the study and had not
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used medication in violation of the exclusion crite-
ria). Sensitivity analysis of the primary variable
was complete case analysis, adjusted for baseline
value and any significant confounders on ITT
population. Anticipating a difference of 1.1% in
tibia total vBMD change over 12 months between
the placebo and treatment group, a standard
deviation of 1.5%, an alpha of 5%, and a statistical
power of 80%, the number of study subjects
needed per group was 30. All tests were two-tailed
and conducted at 0.05 significance level. All anal-
yses were performed using SAS Software version
9.4 (SAS Institute Inc., Cary, NC, USA).
Role of the funding source
The funders had no role in design and conduct of
the study; collection, management, analysis and
interpretation of the data; or in preparation, review
or approval of the manuscript. The corresponding
author had full access to all the data in the study
and had final responsibility for the decision to
submit for publication.
Results
On the basis of BMD criteria, a total of 329 of 969
screened women were eligible for the study (Fig. 1).
Of the 253 women who could be reached, 157
declined participation and six met exclusion crite-
ria, resulting in 90 women enrolled in the study.
Study subjects were included between May 8th
2015 and May 26th 2016 and completed their 12-
month visit between May 9th 2016 and May 24th
2017.
32
Completed the study36Completed the study34
969
329
6
2
2
1
1
Declined participation
Excluded
Current lactobacillus treatment
Current glucocorticoid treatment
Reumathoid arthritis
Current osteoporosis medication
Women were screened
Eligible for inclusion in the ELBOW trial
253 Contacted
Could not be reached
640 Excluded due to BMD criteria*
90 Randomized
Assigned to receive LR6475
(ITT population used for primary analysis)
Assigned to recieve placebo
(ITT population used for primary analysis)
1 Women withdrew consent
10 Withdrew because of adverse event
PP population
6
1
1
1
1
Gastrointestinal disorders
Metabolism and nutrition disorders
Musculoskeletal and connective tissue disorders
Neoplasms benign, malignant and unspecified
Respiratory, thoracic and mediastinal diorders
5454
76
2 Women withdrew consent
7 Withdrew because of adverse event
2
2
1
1
1
Gastrointestinal disorders
Nervous system disorders
Metabolism and nutrition disorders
Neoplasms benign, malignant and unspecified
Skin and subcutaneous tissue disorders
2 Excluded due to gluccocorticoid usage
157
36 PP population
Fig. 1 Patient flow through phases of a randomized trial of L. reuteri 6475 versus placebo for the prevention of bone loss in
older women. Screening, randomization and number of women in the intention-to-treat (ITT) and the per-protocol (PP)
population. L. reuteri 6475 denotes Lactobacillus reuteri 6475.
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The ITT analysis included all study subjects
(n = 90) who were randomized to treatment with
L. reuteri 6475 or placebo. The study groups were
well balanced with regard to baseline characteris-
tics (Table 1). All study subjects were Caucasian. A
total of 70 (76%) patients completed the study, of
whom 34 had been randomized to L. reuteri 6475
and 36 to placebo. Two study subjects (both
randomized to L. reuteri 6475) who had completed
the study were excluded from the PP population
before unblinding due to glucocorticoid treatment
during the study. No study subjects began treat-
ment with osteoporosis medication during the
study. Also in the per protocol population, the
study groups were balanced at baseline (Table S1).
The mean relative change in the primary outcome,
tibia total vBMD, after study completion was
0.83% (95% confidence interval [CI], 1.47 to
0.19%) in subjects randomized to L. reuteri 6475
and 1.85% (95% CI, 2.64 to 1.07%) in those
randomized to placebo in the ITT population. The
mean difference between the groups was 1.02%
(95% CI, 0.02 to 2.03; adjusted P-value = 0.047;
Fig. 2a). Similar results were seen in the PP popu-
lation with a mean change in tibia total vBMD of
0.93% (95% CI, 1.45 to 0.40) in the L. reuteri
6475group and1.86% (95%CI,2.35 to1.36) in
the placebo group (adjusted P-value 0.013; Fig. 2b).
In the ITT population, there were no significant
differences in the secondary outcomes, including
aBMD, trabecular bone volume fraction or bone
microarchitectural indices, bone biomarkers, body
composition, inflammatory markers or HbA1c
between the L. reuteri 6475 group and the placebo
group (Table 2). In the PP population, there was a
significantly lower reduction in trabecular bone
volume fraction in the L. reuteri 6475 group com-
pared to placebo (0.49% [95% CI, 0.97 to
0.01%] vs. 1.29 [95% CI, 1.74 to 0.83],
respectively, with a mean difference of 0.80%
(95% CI, 0.13 to 1.46; adjusted P-value 0.02;
Table S2). In the other secondary outcomes, there
were no differences between the groups in the PP
population.
During the study period, 80% of the subjects
randomized to L. reuteri 6475 and 87% of those
randomized to placebo reported any adverse event
(Tables 3 and S4). Gastrointestinal symptoms were
most common, reported by 47% in the L. reuteri
6475 group and 51% in the placebo group. Change
in bowel habit and flatulence were the most
frequent events in both groups. Adverse events
considered to be related to the treatment were
similar between the groups (40% in L. reuteri 6475
and 44% in placebo). The main reason for discon-
tinuation was adverse events (91% in the L. reuteri
6475 group and 78% in the placebo group,
P = 0.57). Five serious adverse events occurred
during the study: one patient in each study group
was diagnosed with a breast tumour; two patients
in the placebo group suffered from cerebral infarc-
tion; and a transient cerebral ischaemic attack
occurred in a patient in the L. reuteri 6475 group.
As sensitivity analysis, primary and secondary
outcomes were also compared between the
L. reuteri 6475 group and the placebo group for
all subjects who completed the study. In the
analysis of complete cases, a significantly reduced
loss of total vBMD and trabecular bone volume
fraction was observed in those treated with
L. reuteri 6475 compared to those treated with
placebo (Table S3).
Discussion
In this randomized, placebo-controlled, double-
blind, clinical trial, supplementation with L. reuteri
6475 for 12 months resulted in reduced bone loss
in older women with low bone density. The reduc-
tion in total vBMD in the distal tibia was nearly half
as large in women taking 1x1010 CFU day1 of
L. reuteri 6475 than in women taking placebo. The
two groups were well balanced regarding all
anthropometric and lifestyle factors and over all,
the pattern of adverse events was similar.
After attainment of peak bone mass, bone loss
occurs throughout life and is accelerated following
menopause in women [20]. Older women are at a
very high risk for fragility fractures [3], and to
substantially reduce the yearly bone loss in this
group of patients using a naturally occurring
bacteria is a new concept which could lead to a
paradigm shift in the prevention of osteoporosis.
Previous studies in rodents have suggested that
treatment with specific bacterial strains can
improve bone density [15, 16, 21] but the present
study demonstrates for the first time that this may
also be the case in humans.
Trabecular bone, present in the vertebras and
metaphyses of the long bones, has a much higher
turnover than cortical bone, present primarily in
the shafts of the long bones. As a result, diseases
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and medication affecting the skeleton are identified
earlier at skeletal sites rich in trabecular bone [22].
The distal tibia is rich in trabecular bone and is
easily accessible for measurement with HRpQCT, a
technique with the ability to capture even small
alterations in trabecular and cortical bone traits,
which both contribute to the total vBMD. Based
upon this knowledge, a rapid response to any
treatment would most likely be detected as a
change in HRpQCT-derived tibia total vBMD,
which was therefore chosen as the primary out-
come variable in the present trial. Confirming this
hypothesis, L. reuteri 6475 supplementation
reduced loss of total vBMD in all analyses and of
trabecular bone volume fraction in the per protocol
and sensitivity analyses. Given the relatively smal-
ler group to group differences in most of the other
secondary outcome variables, such as change in
spine and hip BMD, in combination with the
greater method-dependent coefficients of varia-
tions (0.7–1.3% for areal BMD measurements),
the statistical power to detect significant treat-
ment-dependent differences for these outcomes
was insufficient. With effects of treatment of the
Table 1 Baseline characteristics for the intention-to-treat populationa
Characteristic L. reuteri 6475 (N = 45) Placebo (N = 45)
Age – year 76.4  1.0 76.3  1.1
Height – cm 162.8  4.8 164.5  5.4
Weight – kg 67.6  8.6 68.6  10.0
Body mass index – kg m2 b 25.5  3.5 25.3  3.3
Run-in period – daysc 55.0 (33.5 to 74.5) 57.0 (40.5 to 71.5)
Follow-up time – daysd 367 (361 to 375) 366 (362 to 380)
Physical health – PSCe 48.6  10.1 49.6  10.0
Mental health – MSCe 55.1  7.7 54.8  8.3
Physical activity – PASEf 103 (78.6 to 138) 111 (78.6 to 146)
Current smoking – no. (%) 2 (4.4) 1 (2.2)
Parental hip fracture – no. (%) 8 (18) 10 (22)
Previous glucocorticoids >3 months – no. (%)g 1 (2.2) 0 (0.0)
High alcohol intake – no. (%)h 0 (0.0) 0 (0.0)
Previous fracture – no. (%)i 12 (27) 20 (44)
Diseases associated with secondary osteoporosis – no. (%)j 11 (24) 10 (22)
FRAX scorek 20.2  6.7 22.0  9.4
Bone mineral density – T score
Lumbar spine 0.90  0.95 1.00  0.95
Total hip 1.14  0.65 1.24  0.53
Femoral neck 1.68  0.59 1.69  0.62
HR-pQCT-derived bone variables
Total volumetric bone mineral density – mg cm3 233  39.9 227  43.6
Trabecular bone volume fraction – % 12.4  2.1 12.5  2.4
Cortical volumetric bone mineral density – mg cm3 759  66.4 733  70.6
Cortical thickness – mm 0.78  0.2 0.72  0.3
Serum markers
N-terminal telopeptide – nmol L1 14.2  3.8 15.6  7.3
Bone-specific alkaline phosphatase – U L1 17.0  3.8 18.9  7.6
C-reactive protein – mg L1 1.65 (0.87 to 2.98) 1.51 (0.80 to 3.82)
Tumour necrosis factor alpha – pg mL1 1.34  0.4 1.38  0.4
HbA1c – mmol mol1 37.9  6.2 37.0  3.8
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observed magnitude, over 140 women would be
needed in each arm to detect statistically signifi-
cant effects on total hip BMD.
In vitro studies indicate that L. reuteri 6475 has the
ability to interfere with TNF-a-mediated
propagation of inflammatory responses in human
macrophages [12, 23]. However, L. reuteri 6475
treatment did not significantly affect the levels of
inflammation markers (TNF-a and hsCRP) in this
trial. Other strains of L. reuteri have also been
reported to reduce blood glucose levels in diabetic
Table 1 (Continued )
Characteristic L. reuteri 6475 (N = 45) Placebo (N = 45)
Body composition – kg
Total fat mass 25.3  5.7 26.2  6.6
Total lean mass 42.7  4.0 42.7  4.9
aMean  SD. For categorical variables numbers and percentages are presented. Non-normally distributed variables are
presented as median with interquartile range. For comparison between groups, Fisher0s exact test was used for
dichotomous variables and t-test or Mann–Whitney U-test were used as appropriate for continuous variables. There were
no significant differences in any of the baseline characteristics between the trial groups consisting of all subjects
randomized. HR-pQCT = high-resolution peripheral quantitative computed tomography, L. reuteri 6475 = Lactobacillus
reuteri 6475. bThe body mass index is the weight in kilograms divided by the squared height in metres. cRun in period was
the number of days between bone measurements and first dose of treatment. dFollow-up time is presented as median and
interquartile range. Data on follow-up time are presented for complete cases (n = 34 in the treatment group and n = 36 in
the placebo group). eMental and physical composite score derived from SF-12 (version 1.0). fThe physical activity score
was estimated using the PASE (physical activity in the elderly) questionnaire. Data on PASE-score were missing for one
participant in the L. reuteri 6475 group. gPrevious glucocorticoid treatment was defined as oral glucocorticoids in a daily
dose equivalent to 5 mg prednisolone for more than 3 months. hA high alcohol intake was defined as drinking more than 3
daily standard drinks (330 mL beer, 90 mL wine, 4 cl spirits) per day over a period of seven days. iPrevious fracture after
the age of 50. jDiseases associated with secondary osteoporosis included any of the following: diabetes, chronic liver
disease, untreated hyperthyroidism, menopause before age 45 years of age, malnutrition, malabsorption, chronic
obstructive pulmonary disease and irritable bowel disease. kThe fracture risk assessment tool FRAX score was calculated
with femoral neck bone mineral density and presented as percentage for the 10-year probability of a major osteoporotic
fracture. Data for all FRAX variables and prior use of bone affecting medications are presented in Tables S5 and S6,
respectively.
Fig. 2 Effect of Lactobacillus reuteri 6475 on total vBMD in older women. Relative change from baseline in tibia total
volumetric bone mineral density (vBMD) after 12 months of treatment with Lactobacillus reuteri 6475 (L. reuteri 6475) or
placebo in the intention-to-treat (a) and the per-protocol (b) population of older women with low bone density. Differences
between the groups are given as mean (95% confidence interval).
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mice [24], and prevent obesity in a mouse model of
the metabolic syndrome [25]. Many studies have
pointed to an association between gut microbiota
and systemic metabolism [26], but in the present
study, treatment with L. reuteri 6475 had no sig-
nificant effect on HbA1c or body composition. As no
differences were detected in the biochemical mark-
ers for inflammation, bone metabolism (NTX and
BALP) or metabolic indices, the present trial does
not provide any explanation regarding the mecha-
nism of the reduced bone loss observed with
L. reuteri 6475 treatment.
The strengths of the present study include the
randomized and double-blind study design with a
prespecified analysis plan, and the fact that the
study population was well characterized with
regard to lifestyle factors and consisted of older
women who are at the highest risk for fragility
fractures. The limitations include the relatively
small sample size, and that the key secondary
outcome variables were not significantly altered by
the L. reuteri 6475 supplementation in the primary
analyses of the ITT cohort, and that the analyses
did not reveal any potential mechanisms for the
observed reduced bone density loss with L. reuteri
6475 treatment. The nonsignificantly higher pro-
portion of prevalent fractures in the placebo group
at baseline could indicate poorer bone health and
perhaps greater bone loss in this group which
could have affected the trial results. Also, it cannot
be ruled out that the proportion of, for example
vitamin D deficiency was higher in the placebo arm
than in the control arm, which could have resulted
in augmented bone loss in the placebo arm.
However, arguing against this hypothesis is the
Table 2 Main analysis of the relative change in the primary efficacy variable and secondary outcomesa
L. reuteri 6475 (N = 45) Placebo (N = 45)
Difference between
groups
Primary outcome
Total volumetric bone mineral density –
(%)
0.83 (1.47 to 0.19) 1.85 (2.64 to 1.07) 1.02 (0.02 to 2.03)
Secondary outcomes
Bone mineral density
Lumbar spine – (%) 0.78 (0.54 to 2.10) 0.08 (1.02 to 1.19) 0.69 (1.05 to 2.43)
Total hip – (%) 0.13 (1.33 to 1.07) 0.90 (2.07 to 0.27) 0.77 (0.91 to 2.46)
Bone geometry and structure
Trabecular bone volume fraction – (%) 0.43 (1.24 to 0.37) 1.31 (2.00 to 0.63) 0.88 (0.17 to 1.93)
Cortical volumetric BMD – (%) 0.67 (1.37 to 0.03) 1.35 (2.15 to 0.54) 0.67 (0.41 to 1.76)
Cortical thickness – (%) 2.40 (4.26 to 0.54) 3.97 (6.14 to 1.80) 1.57 (1.28 to 4.42)
Serum markers
N-terminal telopeptide – (%) 0.35 (13.8 to 13.1) 4.60 (12.8 to 22.0) 4.95 (27.1 to 17.2)
Bone-specific alkaline phosphatase –
(%)
4.83 (12.9 to 3.28) 5.43 (3.38 to 14.2) 10.3 (21.9 to 1.40)
C-reactive protein – (%) 25.1 (47.1 to 97.3) 18.2 (87.4 to 124) 6.89 (121 to 135)
Tumour necrosis factor alpha – (%) 2.79 (8.44 to 14.0) 0.60 (15.5 to 16.7) 2.19 (17.2 to 21.6)
HbA1c – (%) 0.70 (1.45 to 2.86) 1.53 (0.30 to 3.36) 0.83 (3.63 to 1.98)
Body composition
Total fat mass – (%) 3.54 (7.11 to 0.02) 4.10 (8.00 to 0.20) 0.56 (4.67 to 5.79)
Total lean mass – (%) 3.22 (1.66 to 4.78) 2.78 (1.31 to 4.25) 0.44 (1.69 to 2.57)
aThe primary outcome was the relative change after 12 months in total volumetric bone mineral density measured at the
tibia. This analysis was conducted in the intention-to-treat population, which consisted of all individuals who underwent
randomization. Results presented as adjusted means with corresponding 95% confidence interval. Adjustments for
variable baseline values were performed using analysis of covariance (ANCOVA) after multiple imputation. L. reuteri 6475,
Lactobacillus reuteri 6475.
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fact that there were no baseline differences in bone
turnover markers, which would likely be affected
by vitamin D deficiency. The trial may still serve as
a proof of concept and elicit further studies in the
field. Treatment with bisphosphonates, the first-
line osteoporosis therapy, results in much larger
Table 3 Adverse and serious adverse events
L. reuteri 6475 (N = 45) Placebo (N = 45)
Any adverse event – no. (%)a 36 (80) 39 (87)
Gastrointestinal disorders 21 (47) 23 (51)
Change in bowel habit – no. (%) 9 (20) 8 (18)
Flatulence and related conditions – no. (%) 5 (11) 5 (11)
Nausea and vomiting – no. (%) 3 (6.7) 1 (2.2)
Other and unspecified abdominal pain – no. (%) 1 (2.2) 3 (6.7)
Other faecal abnormalities – no. (%) 4 (8.9) 1 (2.2)
Other specified symptoms and signs involving the digestive
system and abdomen – no. (%)
2 (4.4) 1 (2.2)
Musculoskeletal and connective tissue disorders – no. (%) 5 (11) 8 (18)
Primary hip arthroplasty – no. (%) 0 (0.0) 3 (6.7)
Nervous system disorder – no. (%) 5 (11) 5 (11)
Dizziness and giddiness – no. (%) 1 (2.2) 2 (4.4)
Respiratory, thoracic and mediastinal disorders – no. (%) 10 (22) 6 (13)
Acute upper respiratory infection unspecified – no. (%) 3 (6.7) 4 (8.9)
Skin and subcutaneous tissue disorders – no. (%) 2 (4.4) 7 (16)
Pruritus unspecified – no. (%) 1 (2.2) 3 (6.7)
Any fractures – no. (%) 1 (2.2) 2 (4.4)
Adverse events leading to discontinuation of trial agent – no. (%)a 10 (22) 7 (16)
Gastrointestinal disorders 6 (13) 2 (4.4)
Change in bowel habit 2 (4.4) 0 (0.0)
Nausea and vomiting 1 (2.2) 0 (0.0)
Other and unspecified abdominal pain 0 (0.0) 2 (4.4)
Other faecal abnormalities 1 (2.2) 0 (0.0)
Other specified symptoms and signs 2 (4.4) 0 (0.0)
Any treatment-related adverse event – no. (%) 18 (40) 20 (44)
Any serious adverse event – no. (%) 2 (4.4) 3 (6.7)
Neoplasms benign, malignant and unspecified
(incl cysts and polyps) – no. (%)
1 (2.2) 1 (2.2)
Malignant neoplasm, breast unspecified – no (%) 1 (2.2) 1 (2.2)
Nervous system disorder 1 (2.2) 2 (4.4)
Cerebral infarction unspecified – no (%) 0 (0.0) 2 (4.4)
Transient cerebral ischaemic attack unspecified – no (%) 1 (2.2) 0 (0.0)
Any treatment-related serious adverse event – no. (%) 0 (0.0) 0 (0.0)
Death — no. (%) 0 (0.0) 0 (0.0)
Results are presented for the safety population as number of events together with percentage. For comparison between
groups, Fisher0s exact test was used for dichotomous variables. No adverse or serious adverse events were significantly
different between the two treatment groups. L. reuteri 6475, Lactobacillus reuteri 6475.
A more comprehensive presentation of adverse events is presented in Table S4.
aAdverse events are only reported for main categories occurring in at least 10% of the participants of a study group.
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effects on bone density [27, 28] than what was
observed with L. reuteri 6475. However, prolonged
bisphosphonate treatment more than 3–5 years is
not recommended for patients with low-to-moder-
ate fracture risk, limiting long-term use of these
drugs in many patients [29].
In conclusion, daily supplementation with
L. reuteri 6475 for 12 months reduced loss of tibia
total vBMD in older women with low BMD. The
underlying mechanism for this remains to be
elucidated, and further studies are needed to
evaluate the clinical usefulness of L. reuteri 6475
supplementation. Probiotic supplementation could
be a new and promising concept for prevention of
bone loss and osteoporosis.
Acknowledgements
This study was funded by BioGaia AB, by the
Swedish Research Council (VR) grant K2013-52X-
20229-08-5 and the ALF/LUA grant ALFGBG-
437971 from the Sahlgrenska University Hospital.
The manuscript has been handled by an external
editor, Professor Sam Schulman, Thrombosis Ser-
vice, McMaster Clinic, HHS – General Hospital,
Hamilton, Ontario, Canada.
Author contributions
Anna G. Nilsson, Daniel Sundh and Mattias
Lorentzon had full access to all the data in the
study and take responsibility for the integrity of the
data and the accuracy of the data analysis. The
first draft of the manuscript was written by Anna
G. Nilsson and Mattias Lorentzon. All authors
contributed to the design of the study and have
critically revised the manuscript for important
intellectual content and gave final approval of the
submitted manuscript.
Other contributors
Aldina Pivodic, MSc and Anders Pehrson (Statis-
tiska Konsultgruppen, www.stat-grp.se, Stig-
bergsliden 5, Gothenburg, Sweden) have
performed and contributed with all statistical
analyses specified in the statistical analysis plan,
in exchange for financial compensation.
Conflicts of interest statement
The authors have completed and submitted the
ICMJE Form for Disclosure of Potential Conflicts of
Interest. Dr Nilsson has received lecture fees from
Shire and Pfizer. Dr. Sundh states he has no
conflicts of interest. Professor B€ackhed is co-
founder and shareholder of Metabogen AB, a
company partly owned by BioGaiaAB. Professor
Lorentzon has received lecture fees from Amgen,
Lilly, Meda, Renapharma, UCB Pharma, and con-
sulting fees from Amgen, Radius Health, UCB
Pharma, Renapharma and Consilient Health.
References
1 Lorentzon M, Cummings SR. Osteoporosis: the evolution of a
diagnosis. J Intern Med 2015; 277: 650–61.
2 Marshall D, Johnell O, Wedel H. Meta-analysis of how well
measures of bone mineral density predict occurrence of
osteoporotic fractures. BMJ 1996; 312: 1254–9.
3 Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367:
2010–8.
4 Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A,
Tosteson A. Incidence and economic burden of osteoporosis-
related fractures in the United States, 2005-2025. J Bone
Miner Res 2007; 22: 465–75.
5 Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J
Med 2016; 374: 2096–7.
6 Modi A, Siris ES, Tang J, Sen S. Cost and consequences of
noncompliance with osteoporosis treatment among women
initiating therapy. Curr Med Res Opin 2015; 31: 757–65.
7 Backhed F, Fraser CM, Ringel Y et al. Defining a healthy
human gut microbiome: current concepts, future directions,
and clinical applications. Cell Host Microbe 2012; 12: 611–22.
8 Lynch SV, Pedersen O. The human intestinal microbiome in
health and disease. N Engl J Med 2016; 375: 2369–79.
9 Li JY, Chassaing B, Tyagi AM et al. Sex steroid deficiency-
associated bone loss is microbiota dependent and prevented
by probiotics. J Clin Invest 2016; 126: 2049–63.
10 Ohlsson C, Sjogren K. Effects of the gut microbiota on bone
mass. Trends Endocrinol Metab 2015; 26: 69–74.
11 Walter J, Britton RA, Roos S. Host-microbial symbiosis in the
vertebrate gastrointestinal tract and the Lactobacillus reuteri
paradigm. Proc Natl Acad Sci USA 2011; 108(Suppl 1): 4645–
52.
12 Lin YP, Thibodeaux CH, Pena JA, Ferry GD, Versalovic J.
Probiotic Lactobacillus reuteri suppress proinflammatory
cytokines via c-Jun. Inflamm Bowel Dis 2008; 14: 1068–
83.
13 Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwa-
sorn S, Versalovic J. Human-derived probiotic Lactobacillus
reuteri demonstrate antimicrobial activities targeting diverse
enteric bacterial pathogens. Anaerobe 2008; 14: 166–71.
14 Boyce BF, Schwarz EM, Xing L. Osteoclast precursors:
cytokine-stimulated immunomodulators of inflammatory
bone disease. Curr Opin Rheumatol 2006; 18: 427–32.
15 Britton RA, Irwin R, Quach D et al. Probiotic L. reuteri
treatment prevents bone loss in a menopausal ovariectomized
mouse model. J Cell Physiol 2014; 229: 1822–30.
16 Collins FL, Irwin R, Bierhalter H et al. Lactobacillus reuteri
6475 Increases Bone Density in Intact Females Only under an
Inflammatory Setting. PLoS ONE 2016; 11: e0153180.
Prevention of bone loss with Lactobacillus reuteri / A. G. Nilsson et al.
316 ª 2018 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Journal of Internal Medicine, 2018, 284; 307–317
17 Nilsson AG, Sundh D, Johansson L et al. Type 2 diabetes
mellitus is associated with better bone microarchitecture but
lower bone material strength and poorer physical function in
elderly women: a population-based study. J Bone Miner Res
2017; 32: 1062–71.
18 MacNeil JA, Boyd SK. Improved reproducibility of high-
resolution peripheral quantitative computed tomography for
measurement of bone quality. Med Eng Phys 2008; 30: 792–9.
19 Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution
3D-QCT of the human forearm. Technol Health Care 1998; 6:
329–37.
20 Farr JN, Khosla S. Skeletal changes through the lifespan–
from growth to senescence. Nat Rev Endocrinol 2015; 11:
513–21.
21 Hsu E, Pacifici R. From osteoimmunology to osteomicrobiol-
ogy: how the microbiota and the immune system regulate
bone. Calcif Tissue Int 2017; 102: 512–21.
22 Seeman E. Modeling and remodeling: the cellular machinery
responsible for the gain and loss of bone’s material and
structural strength. In: Bilezikian JP, Raisz LG, Martin TJ,
eds. Principles of bone biology, 3rd ed. San Diego, CA:
Elsevier, 2008; 3–28.
23 Thomas CM, Hong T, van Pijkeren JP et al. Histamine derived
from probiotic Lactobacillus reuteri suppresses TNF via
modulation of PKA and ERK signaling. PLoS ONE 2012; 7:
e31951.
24 Lin CH, Lin CC, Shibu MA et al. Oral Lactobacillus
reuteri GMN-32 treatment reduces blood glucose concen-
trations and promotes cardiac function in rats with
streptozotocin-induced diabetes mellitus. Br J Nutr
2014; 111: 598–605.
25 Fak F, Backhed F. Lactobacillus reuteri prevents diet-
induced obesity, but not atherosclerosis, in a strain depen-
dent fashion in Apoe-/- mice. PLoS ONE 2012; 7: e46837.
26 Komaroff AL. The microbiome and risk for obesity and
diabetes. JAMA 2017; 317: 355–6.
27 Liberman UA, Weiss SR, Broll J et al. Effect of oral alen-
dronate on bone mineral density and the incidence of
fractures in postmenopausal osteoporosis. The alendronate
phase III osteoporosis treatment study group. N Engl J Med
1995; 333: 1437–43.
28 Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic
acid for treatment of postmenopausal osteoporosis. N Engl J
Med 2007; 356: 1809–22.
29 Adler RA, El-Hajj Fuleihan G, Bauer DC et al. Managing
osteoporosis in patients on long-term bisphosphonate treat-
ment: report of a task force of the american society for bone
and mineral research. J Bone Miner Res 2016; 31: 1910.
Correspondence: Mattias Lorentzon, Geriatric Medicine, Institute
of Medicine, The Sahlgrenska Academy, Sahlgrenska University
Hospital, Building K, 6th Floor, 431 80 M€olndal, Sweden.
(e-mail: mattias.lorentzon@medic.gu.se).
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Baseline characteristics for the per-
protocol population.
Table S2. Analysis of the primary and key sec-
ondary efficacy variables in the per-protocol pop-
ulation.
Table S3. Sensitivity analysis of the primary and
key secondary efficacy variables for complete cases
in the intention-to-treat population.
Table S4. Adverse and serious adverse events.
Table S5. FRAX variables for the intention-to-treat
population.
Table S6. Prior medications for the intention-to-
treat population.
Prevention of bone loss with Lactobacillus reuteri / A. G. Nilsson et al.
ª 2018 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. 317
Journal of Internal Medicine, 2018, 284; 307–317
